Management of Hyperkalemia in CKD Patients on ACE Inhibitors

Immediate Assessment and Classification

The patient has moderate-to-severe hyperkalemia, with a potassium level of 6.2 mEq/L, which falls in the 6.0-6.4 mEq/L moderate range, approaching severe at ≥6.5 mEq/L, according to the American College of Cardiology 1
The absence of ECG changes does not exclude the need for urgent intervention, as ECG findings are highly variable and less sensitive than laboratory values, as stated by the European Society of Cardiology 1
Verification that the hyperkalemia is not pseudohyperkalemia from hemolysis, repeated fist clenching, or poor phlebotomy technique is necessary before proceeding, as recommended by the American Heart Association 1

Loop diuretics, such as furosemide 40-80 mg IV, are the most appropriate first-line intervention for acute potassium removal in patients with hyperkalemia, as they increase renal potassium excretion by stimulating flow to renal collecting ducts, according to the Mayo Clinic Proceedings 3
The European Society of Cardiology recommends the use of loop diuretics as the primary treatment for hyperkalemia in patients with CKD, as they are effective in removing potassium from the body 1

The American College of Cardiology recommends the use of potassium binders, such as sodium zirconium cyclosilicate (SZC) or patiromer, to facilitate the reinitiation of ACE inhibitors in patients with hyperkalemia, as they are effective in reducing potassium levels and allowing for the continuation of RAAS inhibitors 1, 2
The European Society of Cardiology recommends the use of newer potassium binders, such as SZC or patiromer, over sodium polystyrene sulfonate (Kayexalate) due to the risk of bowel necrosis associated with the older agent 1, 2

The American Heart Association recommends checking potassium and renal function within 1 week of medication changes, and reassessing at 3 days, 1 week, and monthly for the first 3 months on potassium binders, to ensure effective management of hyperkalemia 1, 2
The European Society of Cardiology recommends close monitoring of patients with hyperkalemia, including regular checks of potassium levels and renal function, to prevent complications and ensure effective treatment 1, 2

The American College of Cardiology recommends against permanently discontinuing ACE inhibitors in patients with CKD, as this can lead to worse cardiovascular and renal outcomes, and instead recommends temporary reduction or discontinuation until potassium levels are controlled 1, 2
The European Society of Cardiology recommends against using sodium bicarbonate without documented metabolic acidosis, as it is only indicated when pH <7.35, and against using Kayexalate due to the risk of intestinal necrosis, especially with sorbitol 1, 2